Relmada Therapeutics Inc
Company Profile
Business description
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Contact
2222 Ponce de Leon Boulevard
Floor 3
Coral GablesFL33134
USAT: +1 786 629-1376
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
stocks
Investors overlooking ASX share’s potential
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,735.40 | 83.10 | -0.94% |
| CAC 40 | 7,927.15 | 25.40 | -0.32% |
| DAX 40 | 24,163.55 | 212.98 | 0.89% |
| Dow JONES (US) | 49,526.17 | 537.29 | -1.07% |
| FTSE 100 | 10,243.06 | 47.69 | 0.47% |
| HKSE | 25,675.18 | 287.55 | -1.11% |
| NASDAQ | 26,225.14 | 410.08 | -1.54% |
| Nikkei 225 | 60,815.95 | 593.34 | -0.97% |
| NZX 50 Index | 12,762.92 | 202.09 | -1.56% |
| S&P 500 | 7,408.50 | 92.74 | -1.24% |
| S&P/ASX 200 | 8,505.30 | 72.60 | -0.85% |
| SSE Composite Index | 4,131.53 | 3.86 | -0.09% |